Research Analysts’ Recent Ratings Changes for Cencora (COR)

A number of research firms have changed their ratings and price targets for Cencora (NYSE: COR):

• 2/5/2026 – Cencora was upgraded by analysts at Weiss Ratings from a “hold (c+)” rating to a “buy (b)” rating.
• 2/5/2026 – Cencora had its price target lowered by analysts at Evercore Inc from $440.00 to $420.00. They now have an “outperform” rating on the stock.
• 1/22/2026 – Cencora was upgraded by analysts at Jefferies Financial Group Inc. from an “underperform” rating to a “buy” rating.
• 1/22/2026 – Cencora was upgraded by analysts at Jefferies Financial Group Inc. from a “hold” rating to a “buy” rating. They now have a $440.00 price target on the stock, up previously from $330.00.
• 1/13/2026 – Cencora was given a new $415.00 price target on by analysts at Robert W. Baird.
• 1/5/2026 – Cencora had its price target lowered by analysts at Bank of America Corporation from $380.00 to $360.00. They now have a “neutral” rating on the stock.
• 12/29/2025 – Cencora had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Cencora had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/16/2025 – Cencora was given a new $392.00 price target on by analysts at Robert W. Baird.
• 12/15/2025 – Cencora had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is presently 28.85%.

Insider Activity at Cencora

In other news, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer owned 66,726 shares in the company, valued at $23,669,713.98. This trade represents a 7.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the sale, the executive vice president directly owned 23,891 shares in the company, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 20,316 shares of company stock valued at $7,151,265. 0.38% of the stock is owned by company insiders.

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.